A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement
Sponsor: Daiichi Sankyo
Listed as NCT00398216, this PHASE2 trial focuses on Hip Replacement and Thrombosis and remains completed. Sponsored by Daiichi Sankyo, it has been updated 11 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2024 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ajax, Canada , Austin, United States , Cambridge, Canada , Chernivtsy, Ukraine , Dnipro, Ukraine , Donetsk, Ukraine , Guelph, Canada , Gyula, Hungary , Hartford, United States , Hellerup, Denmark and 19 more locations